A 20-year-old woman had waves of stomach pain for months. She was eventually diagnosed with stage 2 colon cancer.

Lead

Katie Davis, a 20-year-old college student in Pennsylvania, experienced intermittent, wave-like upper abdominal pain in late 2024 that she initially and repeatedly attributed to benign causes. After a brief urgent-care visit and later an emergency-room workup prompted by chills and vomiting, imaging showed an inflamed colon and fluid; a colonoscopy and biopsy confirmed stage 2 colon cancer. She underwent surgery, began chemotherapy but switched to an oral regimen after severe side effects, and completed treatment in June 2025 before being declared cancer-free. Davis now faces ongoing surveillance with quarterly blood tests and annual colonoscopies while advocating for greater awareness of colorectal symptoms in young adults.

Key takeaways

• Katie Davis, now 21, first felt episodic upper-abdominal pain at age 20 in 2024 and sought care after symptoms worsened and she developed chills and vomiting.
• Emergency imaging noted colon inflammation and free fluid; a colonoscopy and biopsy led to a diagnosis of stage 2 colon cancer in late 2024.
• Initial plan called for three months of chemotherapy after surgery, but severe side effects — including extreme fatigue, neuropathy and transient vision loss — required switching to oral-only chemotherapy and extending treatment to six months.
• Davis completed chemotherapy in June 2025 and was declared cancer-free shortly afterwards; follow-up monitoring includes blood tests every three months and annual colonoscopy.
• She credits prompt escalation from urgent care to ER and the colonoscopy for the timely diagnosis, and she has joined the Colorectal Cancer Alliance for peer support and information.
• Davis continued attending college courses and internships during treatment when possible, highlighting the practical and emotional burden of care for young adults balancing school and cancer therapy.
• Her case underscores growing clinical attention to colorectal cancer symptoms in adults under 50, a cohort that has experienced rising incidence in recent years.

Background

Katie Davis was a junior and marketing major at Westchester University in Pennsylvania when abdominal pain began in 2024. Her daily routine combined classes, a job at Playa Bowls and sorority activities; the pain was sporadic, short-lived and located in the upper right abdomen, which initially made both Davis and clinicians consider common gynecological or benign gastrointestinal causes. After an urgent-care visit at a remote location without ultrasound capability, clinicians suggested a possible ovarian cyst and advised monitoring until her next menstrual period.

When chills, nausea and vomiting followed a few days later, Davis presented to an emergency room. CT and ultrasound performed there showed inflammation of the colon and free intraperitoneal fluid, findings that can reflect infection, inflammatory bowel disease, trauma, or malignancy. The ER team arranged a colonoscopy to obtain tissue for diagnosis. Although colorectal cancer is less common in patients in their early 20s, clinicians now emphasize evaluation when warning signs escalate or imaging is abnormal.

Main event

During the colonoscopy and subsequent biopsy in late 2024, clinicians identified a mass in Davis’s colon. The endoscopist told Davis and her mother he was “pretty positive” the lesion was malignant based on its appearance and his experience; pathology confirmed stage 2 colon adenocarcinoma. Davis described feeling numb and confused on receiving the diagnosis and later reflected on subtle cues she had noticed before the formal diagnosis.

Surgical resection was performed as the first major therapeutic step. The multidisciplinary plan initially included adjuvant intravenous chemotherapy for roughly three months to reduce recurrence risk after surgery. However, Davis developed severe treatment-related toxicities during the planned regimen, including profound fatigue, persistent nausea, peripheral neuropathy described as temperature-sensitive “pins and needles,” and episodes when her vision would transiently black out.

Because of these toxicities — and after family research into oxaliplatin-related visual side effects — Davis and her care team shifted to an oral-only chemotherapy regimen. That change doubled the intended treatment duration from about three months to six months but reduced the need for frequent infusion-center visits and improved tolerability enough for her to continue some daily activities. She completed chemotherapy in June 2025 and was subsequently declared cancer-free following follow-up evaluation.

Analysis & implications

Davis’s case highlights two intersecting clinical challenges: atypical presentation in a young adult and management of chemotherapy toxicity. Intermittent, short-lived abdominal pain in young people is often benign, but clinicians use red flags — progressive symptoms, systemic signs such as fever or chills, abnormal imaging — to determine when to pursue invasive diagnostics like colonoscopy. In this case, escalation from urgent care to ER imaging triggered the diagnostic pathway that found a stage 2 lesion.

The treatment course illustrates trade-offs between regimen intensity and tolerability. Oxaliplatin-containing regimens are standard adjuvant options for some stage 2 and stage 3 colon cancers but carry risks such as cumulative neuropathy and, less commonly, ocular or visual disturbances. Transitioning to oral agents prolonged therapy but reduced acute, severe adverse events that had compromised Davis’s quality of life and function.

At a population level, colorectal cancer incidence has risen among adults under 50 over recent decades, prompting guideline groups and clinicians to rethink risk thresholds and screening strategies for younger adults. For individuals like Davis, who are still in school and working, the burden of cancer care includes academic disruption, financial and logistical strain, and psychosocial impacts that extend beyond the immediate medical outcomes.

Comparison & data

The timeline above summarizes Davis’s diagnostic and treatment milestones. While her therapeutic plan evolved due to toxicity, the interval from symptom onset to definitive diagnosis and curative-intent surgery was measured in months rather than years, which clinicians view as favorable for prognosis in stage 2 disease. Surveillance going forward will focus on blood markers and periodic colonoscopy to detect recurrence early.

Reactions & quotes

The clinical team’s comments and Davis’s reflections help illustrate the emotional and procedural contours of her journey. Her description of symptom timing and the shock of diagnosis convey the patient experience:

“It was on and off, it would come in waves.”

Katie Davis, patient

When told the mass appeared malignant, the performing physician used cautious professional language to convey concern based on endoscopic findings:

“He said he’d been doing it for long enough that he could kind of tell.”

Endoscopist involved in Davis’s care (as recalled by patient)

On finishing treatment and reflecting on lessons for others, Davis emphasized body awareness and peer support:

“I’m glad that I learned to listen to my body.”

Katie Davis, patient

Unconfirmed

• The patient’s placement in a separate recovery room after colonoscopy was interpreted by her as an early sign clinicians suspected cancer; that perception is subjective and not independently verified in clinical records.
• The family’s conclusion that oxaliplatin caused Davis’s transient vision loss is plausible given known side effects, but a direct causal attribution was not confirmed with ophthalmologic diagnostics in the publicly available account.
• Claims that colorectal cancer has become the leading cause of cancer death for people under 50 derive from trend analyses; the precise ranking can vary by dataset and year and should be confirmed against up-to-date national mortality statistics.

Bottom line

Katie Davis’s case demonstrates that colorectal cancer can present with intermittent, non‑specific pain in young adults and that timely escalation from local urgent care to imaging and endoscopic assessment can produce a curative diagnosis at a surgically treatable stage. Her treatment required adjustment when standard chemotherapy produced severe, life‑altering side effects, emphasizing the need to balance efficacy with tolerability — especially for patients who must maintain education and work obligations.

For clinicians and health systems, this case underscores the importance of maintaining diagnostic vigilance when symptoms progress or systemic signs appear, regardless of patient age. For the public, Davis’s experience highlights the value of paying attention to persistent or worsening symptoms and seeking re-evaluation if initial conservative management does not resolve concerning signs.

Sources

• Business Insider (news article; original patient interview)
• Colorectal Cancer Alliance (nonprofit/advocacy; patient support and information)
• American Cancer Society (health organization; background on colorectal cancer incidence and screening)